Abstract:Despite significant treatment advances, the poor long-term prognosis for children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) persists. The application of immune cell-based therapies, such as chimeric antigen receptor-expressing T cells and bispecific T-cell engagers, has improved progression-free survival for many B-ALL patients. However, many of these patients still experience disease relapse. While tumours are widely recognized to influence T cell function, this relationship has not been extensively studied in B-ALL. A clinically silent pre-leukemic phase usually precedes childhood B-ALL. Since only a small percentage of children subsequently develop disease, the impact of pre-leukemia on T cell function remains elusive. To address this knowledge gap, we investigated the development of T cell dysfunction in B-ALL and explored ways to restore it using in situ and transplanted leukemia models Using the Emu-Ret transgenic mouse model of hyperdiploid B-ALL, we investigated the induction of exhaustion-associated marker expression (PD-1, CTLA-4 and Tim-3) on T cells. Longitudinal analysis of marker expression revealed that an upregulation of multiple immune checkpoints such as PD-1 and Tim-3, on T cells occurred only in the presence of leukemia cells, not during the extended preleukemia phase. This suggests that T cell exhaustion occurs exclusively during the established malignancy phase, highlighting the evolving nature of T cell responses as disease progresses. Next, we measured exhaustion-associated marker expression in a syngeneic model of transplanted B-ALL. While expression of PD-1 and Tim-3 on T cells correlated with disease progression, a significant increase in these markers was already detectable at low leukemia burden. This indicates that T cell exhaustion is not merely a reflection of high disease burden and highlights the differing impact exerted by preleukemic and leukemic cells on T cells. Phenotypically exhausted T cells from both mouse models showed reduced proliferation, activation, and cytokine secretion. Previously, we have demonstrated the ability of toll-like receptor (TLR) ligands to induce immune control over B-ALL cells. Thus, we investigated the impact of CpG oligodeoxynucleotides (CpG ODN), a ligand for TLR-9, to overcome T cell dysfunction. The treatment of leukemia bearing mice with CpG ODN led to a decrease in PD-1 and Tim-3 expression on T cells, which was also associated with a reduction in leukemia burden. Lastly, the administration of a checkpoint blockade antibodies, with or without TLR agonists as adjuvant therapy led to increased survival of leukemia bearing mice. Overall, this study demonstrates the functional impact of interactions between B-ALL cells and the immune system. The findings from this study may inform therapeutic approaches to overcome B-ALL immune evasion mechanisms and enhance patient outcomes. Citation Format: Tanmaya Atre, Gregor S.D Reid. Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B012.

BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists

CpG Oligodeoxynucleotide-Induced Apoptosis of B-Lineage Acute Lymphoblastic Leukemia is Through C-MYC/P53/BAX Signaling Pathway

Combination Therapy with CpG Oligodeoxynucleotide and Imatinib Can Reverse the Drug Resistance when Applied Alone Through Promoting BAX Activation and Overcoming BCR-ABL1-independent PI3K/AKT Activation.

BACH2-mediated CD28 and CD40LG axes contribute to pathogenesis and progression of T-cell lymphoblastic leukemia

Heterogeneity of Toll-like Receptor 9 Signaling in B Cell Malignancies and Its Potential Therapeutic Application

Role of chemokines in T-cell acute lymphoblastic Leukemia: From pathogenesis to therapeutic options

Targeting chemokines for acute lymphoblastic leukemia therapy

Patient's T Cell Functionality Determines Blinatumomab-Mediated Killing of B-ALL Leukemia Cells

Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia

Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration

Abstract B012: Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia

ERG and c-MYC regulate a critical gene network in BCR::ABL1-driven B cell acute lymphoblastic leukemia

The Impact of T Cell Immunity on Chemotherapy Response in Childhood Acute Lymphoblastic Leukemia

Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors

MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies.

Bafilomycin A1 Targets Patient-Derived CD34+CD19+ Leukemia Stem Cells

[BAX Deletion Accelerates Progression of BCR-ABL-Induced B-ALL in Mice].

BCL9/BCL9L Promotes Tumorigenicity Through Immune-Dependent and Independent Mechanisms in Triple Negative Breast Cancer

Phosphorylation stabilized TET1 acts as an oncoprotein and therapeutic target in B cell acute lymphoblastic leukemia

Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia.

CD9 Blockade Suppresses Disease Progression of High-Risk Pediatric B-cell Precursor Acute Lymphoblastic Leukemia and Enhances Chemosensitivity.